Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201204052 Principal Investigator: Westervelt, Peter
Title: A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors
Phase: III Disease Site: Other Hematopoietic
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to find out if an investigational drug called US-ATG-F can be safely used to prevent graft versus host disease (GVHD).
 
More Information:
CT.gov link
Internal Protocol Documents (requires Siteman administrative database password)